Archive | Clinical Diagnostics and Tools

We will report important news in clinical diagnostics and life science tools as it affects our portfolio.The top market sectors are sequencing and molecular diagnostics.

Q2 Review of Pure Play Diagnostic Companies:Bargain Hunting in ABAX,GPRO,QGEN

Summary of Q2 Earnings and Valuation Metrics of Selected Pure Play Dx Companies Company Ticker Price RevEst Q1Rev Q2Rev Price Mcap P/S PE PEG 5/18/11 $M Yr. $M 15-Aug $M GenProbe GPRO 80 579 143 136 60 2900 5 29 2 Abaxis ABAX 28 157 37.5 36 23.9 544 3.46 41 2.3 Alere ALR 2360 […]

Continue Reading 0

Rayno Life Science Tools and Diagnostics: What’s Hot and Not?

It was a tough week in Life Science Tools and Diagnostics with many crosscurrents: debt ceiling uncertainty, earnings shortfalls, lackluster economic data and European debt crisis. The usual positive buzz from the AACC offered little support. We will provide an updated financial comparison of all stocks in our diagnostic/tools index at the end of Q2 […]

Continue Reading 0

Illumina Guidance Drags Down Life Science Tools Sector: Maintain Caution

Dog Days of Summer Lie Ahead- Q3 Seasonality in Life Sciences is Weak A vicious 16% sell-off in Illumina Inc. (ILMN $58.43) due to revised 2011 guidance and subsequent analysts’ reduced outlook. Concerns about sales growth are a new concern. Revenue for Q2 was $287M a 36.5 %increase over Q2 2010 and an EPS of […]

Continue Reading 0

Rayno Life Science Portfolio Tools and Dx-Big Winners YTD: CRA,CSII,EXAS,GPRO

Diagnostics is Still a Hot Ticket The Rayno Life Science Tools and Diagnostics Portfolio is up 12% YTD with big winners Celera up 31%, recently acquired by Quest Diagnostics (DGX), Cardiovascular Systems (CSII) up 32.5%,Exact Scientific (EXAS) up 42%, and GenProbe (GPRO) up 19.6%. In the news today Alere (ALR $37.93) announced an unsolicited $369M […]

Continue Reading 0

Rayno Life Science Tools And Dx Portfolio Update:Immucor Beats 6/20 update

11/29/11 No new buys on tools/Dx since summer meltdown and Illumina (ILMN) miss. 6/20/11 NASDAQ (2632) Market stabilizing after 7% correction.QQQ down <1%. IBB up 10% YTD. Mid-cap biopharms are up 1.6% as of mid-day. Mixed tape in Dx and Tools with winners BLUD, ILMN, NEOG and SQNM; losers are down less than 1%. Qiagen(QGEN) still […]

Continue Reading 0

JPMorgan Healthcare Conference…2009

JPMorgan Healthcare Conference Monday briefing: Rod Raynovich Webcast at: Biotech Valuations at trough levels About 4000 attendees consisting of mutual and hedge fund investors,VC’s, Company executives and their PR legions registered the first day of the conference that eventually is expected to see 5500 by Thursday. With many markets weak and suffering from the […]

Continue Reading 0